Company Overview and News

 
LNGG / Linn Energy Inc S-8

2018-10-16 sec.gov
S-8 As filed with the Securities and Exchange Commission on October 16, 2018 Registration No. 333-
LNGG

 
LNGG / Linn Energy Inc FORM 8-K (Current Report)

2018-09-27 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 LNGG

37
For Oil Price Exposure And Yield Buy Black Stone Minerals

2018-09-25 seekingalpha
For years trusts like BPT have offered exposure to rising commodity prices in a high-yield vehicle; however, many publicly traded trusts are nearing the end of their finite lifespans.
PIO XOM LNGG CHKVP CXO PIONF CHKDH CHKVZ XTO CHKDG CHKDJ VNR CHKDP VNRBP LINEQ CKRGZ NBL BSM VNRR CHKWZ BPT CHK.WI CHK VNRAP VNRCP LINE

 
LNGG / Linn Energy Inc 8-K/A (Current Report)

2018-09-25 sec.gov
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LNGG

 
LNGG / Linn Energy Inc FORM 8-K (Current Report)

2018-09-24 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 LNGG

14
E&P Skirmish In The Shallow STACK? Alta Mesa, Chaparral And Gastar

2018-09-24 seekingalpha - 4
Gastar Exploration recently hired investment bankers to pursue the sale of the company after its primary creditor, Ares, essentially forced the issue.
LINEQ CAMZF CAMZD GST-A LNGG CTLR GST-B DVN GST NFX EOG SPAQ CHAP MRO CLR LINE

 
LNGG / Linn Energy Inc 8-K (Current Report)

2018-09-21 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LNGG

 
LINN Energy, Inc. Announces the Estimated Tax Characteristics of Its Spin-Off of Riviera Resources

2018-09-20 globenewswire
HOUSTON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB: LNGG) (“LINN” or the “Company”) announces that is has posted on its website IRS Form 8937 regarding the estimated federal income tax characteristics of its spin-off of Riviera Resources, Inc. (“Riviera”) from LINN (the “Spin-Off”) that was completed on August 7, 2018.
LINEQ RVRA LNGG LINE

 
LINN Energy and Roan Holdings Announce Definitive Agreement to Combine 100% of Their Interests in Roan LLC Into a New Publicly Traded Pure Play Company, Roan Resources, Inc.

2018-09-18 globenewswire
HOUSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB: LNGG) (“LINN” or the “Company”) today announced that it has entered into a master reorganization agreement (the “Reorganization Agreement”) with Roan Holdings, LLC (“Roan Holdings”) and Roan Resources LLC (“Roan LLC”), to effectuate the reorganization of LINN’s and Roan Holdings’ respective 50% equity interests in Roan LLC under a newly formed company, Roan Resources, Inc.
LINEQ LNGG DTK LINE

28
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha - 3
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

 
Abraxas Petroleum: Opportunity To Deliver Positive Cash Flow In 2019

2018-09-14 seekingalpha
If Abraxas can maintain drilling inventory and production levels with a $110 million capital expenditure budget in 2019, then it is projected to have $19 million in positive cash flow.
LINEQ LNGG AXAS LINE

 
Riviera Resources: A Cheap, Long-Term Play With Limited Risk

2018-09-06 seekingalpha
Safety and the oil and gas space is not generally considered synonymous these days, but one firm, Riviera Resources, stands out.
LINEQ RVRA LNGG LINE

 
Riviera Resources, Inc. Announces Board Approval of $100 Million Share Buyback, Approval for Blue Mountain Midstream LLC to Design Second Cryogenic Plant, and Plans to Pick Up an Operated NW Stack Rig in the Fourth Quarter

2018-08-22 globenewswire
HOUSTON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Riviera Resources, Inc. (OTCQX: RVRA) (“Riviera” or the “Company”) announces the following:
LINEQ RVRA LNGG LINE

 
LNGG / Linn Energy Inc 8-K (Current Report)

2018-08-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LNGG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...